Ahmed Sana, Naz Arooj, K Mahnoor
Internal Medicine, Smt. Kashibai Navale Medical College, Mumbai, IND.
Medicine, Frontier Medical and Dental College, Abbottabad, PAK.
Cureus. 2023 Feb 17;15(2):e35102. doi: 10.7759/cureus.35102. eCollection 2023 Feb.
Prader-Willi syndrome (PWS) is the most common genetic obesity syndrome. The clinical features of this condition include childhood obesity, hyperphagia, infantile hypotonia, hypogonadism, short stature, and characteristic facial features. The leading cause of morbidity and mortality in PWS is hyperphagia and resultant obesity. Here, we highlight the effectiveness of glucagon-like peptide-1 (GLP-1) agonists by reporting an interesting case of successful rapid weight loss in an adult with PWS using GLP-1 agonists - exenatide and liraglutide. To the best of our knowledge, this report presents the first clinical evidence supporting the use of GLP-1 receptor agonists in the treatment of genetic obesity syndromes; our patient lost a total of 125 lbs on GLP-1 analog and continues to lose weight.
普拉德-威利综合征（PWS）是最常见的遗传性肥胖综合征。该病症的临床特征包括儿童期肥胖、食欲亢进、婴儿期肌张力减退、性腺功能减退、身材矮小以及特征性面部容貌。PWS发病和死亡的主要原因是食欲亢进及由此导致的肥胖。在此，我们通过报告一例有趣的病例来突出胰高血糖素样肽-1（GLP-1）激动剂的有效性，该成年PWS患者使用GLP-1激动剂艾塞那肽和利拉鲁肽成功快速减重。据我们所知，本报告提供了首个支持使用GLP-1受体激动剂治疗遗传性肥胖综合征的临床证据；我们的患者使用GLP-1类似物共减重125磅，且仍在继续减重。
